Clinical Research Directory

Inclusion Criteria: To be enrolled in this trial, patients must meet all of the following inclusion criteria: 1. Locally advanced or metastatic gastric neuroendocrine carcinoma (NEC), hyperproliferative neuroendocrine tumor (NET G3) or mixed neuroendocrino-non-neuroendocrine tumor (MiNEN), as demonstrated by pathology (WHO classification criteria 2019), may also be included; 2. Have not received systematic anti-tumor therapy before; 3. Have received radical treatment in the past and have no treatment interval from the end of chemotherapy, radiotherapy, or chemoradiotherapy to relapse for at least 6 months (the end time of the last chemotherapy cycle/the end time of the last radiotherapy); 4. There are measurable lesions defined by the RECIST 1.1 standard; 5. At least 18 years old; 6. ECOG physical condition: 0-1 score; 7. Expected survival of more than 3 months; 8. If the major organs function normally, the following criteria are met: 1. Blood routine examination: hemoglobin (Hb) ≥90g/L; Absolute neutrophil count (ANC) ≥1.5×10\^9/L; Platelet (PLT) ≥100×10\^9/L; White blood cell count (WBC) ≥3.0×10\^9/L; 2. Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (tumor liver metastasis, ≤5×ULN); Serum total bilirubin (TBIL) ≤1.5×ULN (Gilbert syndrome subjects, ≤3×ULN); Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥50ml/min; 3. Coagulation function: activated partial thromboplastin time (APTT), International Standardized ratio (INR), prothrombin time (PT) ≤1.5×ULN; 9. The subjects voluntarily joined the study, signed the informed consent, and the compliance was good. Exclusion Criteria: Patients with any of the following conditions were excluded from the study: 1. The presence of a serious illness or medical condition, including but not limited to the following: 1. Known recurrence in situ or metastasis at any other site; 2. systemic active infection (i.e. infection resulting in body temperature ≥38 ° C); 3. Clinically significant intestinal obstruction, pulmonary fibrosis, renal failure, liver failure, or symptomatic cerebrovascular disease; 4. Severe/unstable angina, New York Heart Association (NYHA) Class III or IV symptomatic congestive heart failure; 5. Clinically significant gastrointestinal bleeding; 6. Known presence of human immunodeficiency virus (HIV) or acquired conventional immunodeficiency syndrome (AIDS) - associated disease, or active hepatitis B or C; 2. Pregnant or lactating women; 3. The researcher considers it inappropriate to enter this study.